

## Human CD40L / CD154 protein, DDDDK tag (active, multimeric)

## Cat. No. GTX65635-pro

Applications	Functional Assay	Package
Species	Human	10 µg

## PRODUCT

Summary	Multimeric Proteins are high activity constructs in which two trimeric TNFSF ligands are linked via the oligomeric collagen domain of ACRP30 [ACRP30headless] and therefore mimic the membrane-bound forms of the proteins.
---------	---

## Applications

## Application Note

Induces B cells activation (as demonstrated by dose-dependent upregulation of CD86) (ED<sub>50</sub>: <1ng/ml).

Product Note	Binds to human CD40.
--------------	----------------------

## Properties


Form	Lyophilized powder
Buffer	Reconstitute with 100µl ddH <sub>2</sub> O to 0.1mg/ml. Lyophilized from 0.2µm-filtered PBS.
Preservative	No preservatives
Storage	Store at -20°C or below. After reconstitution, keep as concentrated solution. Aliquot and avoid freeze-thaw cycles.
Region/Sequence	N-terminal DDDDK-Tag; Human CD40L (a.a.116-261) is fused at the N-terminus to mouse ACRP30headless (a.a.18-111).
Expression System	CHO cells
Purity	??95% by SDS-PAGE.
Endotoxin	< 0.01 EU/µg
Conjugation	Unconjugated
Note	For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.



For full product information, images and publications, please visit our [website](#).

Date 2026 / 01 / 30 Page 1 of 2

## DATA IMAGES



## GTX65635-pro Image

GTX65635-pro CD40L protein (multimeric) does not need an enhancer to induce B cells activation. Method: PBL cells were incubated in 96-well plates ( $2 \times 10^5$  cells/well in  $100\mu\text{l}$  RPMI supplemented with 10% FCS) for 24 hours at  $37^\circ\text{C}$  with the indicated concentration of CD40L (multimeric) or CD40L in the presence and absence of  $1\mu\text{g}/\text{ml}$  Enhancer. Cells were washed with PBS and stained with CD86-PE antibody and CD19-FITC antibody, and then analyzed by flow cytometry.



For full product information, images and publications, please visit our [website](#).

Date 2026 / 01 / 30 Page 2 of 2